Formulation Development
KemPharm Announces Top-Line Results From Clinical Trial Evaluating the Safety & Pharmacokinetics of Higher-Dose SDX
KemPharm, Inc. recently announced top-line results from its clinical trial exploring the safety and pharmacokinetics of serdexmethylphenidate (SDX) delivered at doses higher than those studied…
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated With Schizophrenia
atai Life Sciences recently announced positive topline data from its Phase 2a study of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS). The 32-patient, single-arm,…
HiberCell to Collaborate With Merck on Phase 2 Clinical Trial of Odetiglucan in Combination With KEYTRUDA in Patients With Metastatic Breast Cancer
HiberCell recently announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with….
Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
Pfizer to Acquire Arena Pharmaceuticals for $6.7 Billion
Pfizer Inc. and Arena Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical-stage company developing….
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
Akoya Biosciences Announces Groundbreaking Collaboration With PathAI to Combine Spatial Biology With AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers
Akoya Biosciences, Inc. and PathAI recently announced a collaboration to advance the discovery and validation of novel predictive biomarkers for immunotherapies. The partners will leverage…
NextCure & Collaborators Provide Data on Targets in Development
NextCure, Inc. recently announced new data in oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, and on…
Arrivo BioVentures Emerges From Stealth Mode With a Robust Pipeline & Promising Data
After launching the company over 5 years ago with a team of seasoned serial entrepreneurs, $49 million in committed capital, and the promise to assemble…
Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
Halberd Corporation has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune…
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination With Pembrolizumab in Metastatic Breast Cancer
Intensity Therapeutics, Inc. recently reported safety, pharmacokinetic, biomarker, and efficacy data using INT230-6, with and without pembrolizumab, in heavily pretreated refractory breast cancer patients as part of the….
UniQure Announces Pivotal Phase 3 HOPE-B Study Meets Primary Endpoint for Hemophilia B Gene Therapy
CSL Behring and uniQure N.V. recently announced that etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe to moderately…
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating Selective Aldosterone Synthase Inhibitor in Patients With Uncontrolled Hypertension & High Plasma Aldosterone
CinCor Pharma, Inc. recently announced the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective, oral small molecule…
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined With Chemotherapy in Patients With First-Line Non-Squamous Non-Small Cell Lung Cancer
Checkpoint Therapeutics, Inc. recently announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum…
BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing
BrainStorm Cell Therapeutics Inc. and Catalent recently announced that the technology transfer for NurOwn manufacturing at Catalent’s facility has been finalized….
Salubrent Pharma Solutions Strengthens Analytical Team
Salubrent Pharma Solutions recently it is continuing to build upon its vision of becoming a full service, technology-focused CDMO by filling the positions of Director of Analytical Development and Analytical Development Chemist at….
Sequana Medical Announces Positive Interim Results of SAHARA DESERT, the alfapump DSR Study in Heart Failure Patients With Persistent Congestion
Sequana Medical NV recently announced positive interim results from six patients in SAHARA DESERT, the safety and feasibility study of alfapump DSR (Direct Sodium Removal)…
Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award & Looks Back on a Stable Year Under Ongoing Pandemic Circumstances
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan’s 2021 Global Customer Value Leadership Award in the…
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge With Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company
Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. recently announced they have entered into a definitive business combination agreement…..
Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease
Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….
